Abstract
The study was undertaken to investigate the efficacy and safety of Saccharomyces boulardiicombined with proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori related peptic ulcer. One hundred patients with H. pylori infection were randomized in two groups: intervention and control group. Both groups were treated with the standard triple eradication therapy (omeprazole, amoxicillin and clarithromycin). The effective rate of the improvement in the treatment group was 96.0%, and was significantly higher than the control group (62.0%) (x2 = 6.899, P < 0.01). The pH of the two groups was also elevated after the treatment (P < 0.05, P < 0.05); the positive culture rate of bacteria increased obviously and there was significant difference between the two groups (P < 0.05). The eradication rate of H. pylori in the treatment group was 84.4% and was significantly higher than the control group (64.4%) (x2 = 5.848, P < 0.01). In addition, the rate of recurrence in the treatment group was 10.0%, while in the control group it was 26.0% after treated for one year (x2 = 11.584, P < 0.01). There was significant difference in the rate of adverse events between the two groups (15.6 and 57.8% of the treatment group and control group, respectively; x2 = 18.936, P < 0.01). Therefore, S. boulardii with PPI-based triple therapy for peptic ulcer is effective with a low recurrence rate and can reduce the incidence of adverse events. Key words: Peptic ulcer, Helicobacter pylori, Saccharomyces boulardii, proton pump inhibitor (PPI)-based triple therapy.
Highlights
Peptic ulcer (PU) is a common infectious disease in the digest system, including gastric ulcer (GU) and duodenal ulcer (DU)
It has been suggested that S. boulardii, a kind of nonpathogenic yeast, may be effective and safe in preventing antibioticassociated diarrhea (AAD) (Katz, 2006) while eradicating H. pylori infection (Cremonini et al, 2002; Duman et al, 2005)
The positive rate of bacteria in the treatment group was significantly lower than that in the control group, revealing S. boulardii can inhibit bacterial overgrowth and regulate flora disturbance to maintain the balance of micro-ecological system in the stomach
Summary
Peptic ulcer (PU) is a common infectious disease in the digest system, including gastric ulcer (GU) and duodenal ulcer (DU). Reports of the effectiveness of H. pylori eradication therapy are mounting (Chung et al, 2012; Kuo et al, 2012), suggesting the vital value to eradicate H. pylori in curing ulcer, preventing recurrence and reducing complications. 1 to 2 weeks of PPI-based triple therapy is regarded as the regular treatment for H. pylori-infectious peptic ulcer. It can cure ulcer efficiently though inhibiting gastric acid secretion and H. pylori elimination quickly. In recent years, to investigate the potential role of Saccharomyces boulardii in reducing H. pylori treatment-related side effects while improving the eradication rate, we added S. boulardii to PPI-based triple therapy to cure H. pylori-infectious PU and the results show a satisfactory clinical effect for the prevention and treatment of the disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
